Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 698

1.

CIC Mutation as a Molecular Mechanism of Acquired Resistance to Combined BRAF-MEK Inhibition in Extramedullary Multiple Myeloma with Central Nervous System Involvement.

Da Vià MC, Solimando AG, Garitano-Trojaola A, Barrio S, Munawar U, Strifler S, Haertle L, Rhodes N, Teufel E, Vogt C, Lapa C, Beilhack A, Rasche L, Einsele H, Kortüm KM.

Oncologist. 2019 Oct 18. pii: theoncologist.2019-0356. doi: 10.1634/theoncologist.2019-0356. [Epub ahead of print]

PMID:
31628267
2.

Generation and infusion of multi-antigen-specific T cells to prevent complications early after T-cell depleted allogeneic stem cell transplantation-a phase I/II study.

Roex MCJ, van Balen P, Germeroth L, Hageman L, van Egmond E, Veld SAJ, Hoogstraten C, van Liempt E, Zwaginga JJ, de Wreede LC, Meij P, Vossen ACTM, Danhof S, Einsele H, Schaafsma MR, Veelken H, Halkes CJM, Jedema I, Falkenburg JHF.

Leukemia. 2019 Oct 17. doi: 10.1038/s41375-019-0600-z. [Epub ahead of print]

PMID:
31624377
3.

RAL GTPases mediate multiple myeloma cell survival and are activated independently of oncogenic RAS.

Seibold M, Stühmer T, Kremer N, Mottok A, Scholz CJ, Schlosser A, Leich E, Holzgrabe U, Brünnert D, Barrio S, Kortüm KM, Solimando AG, Chatterjee M, Einsele H, Rosenwald A, Bargou RC, Steinbrunn T.

Haematologica. 2019 Oct 10. pii: haematol.2019.223024. doi: 10.3324/haematol.2019.223024. [Epub ahead of print]

4.

Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma.

Ludwig H, Poenisch W, Knop S, Egle A, Schreder M, Lechner D, Hajek R, Gunsilius E, Krenosz KJ, Petzer A, Weisel K, Niederwieser D, Einsele H, Willenbacher W, Melchardt T, Greil R, Zojer N.

Br J Cancer. 2019 Sep 27. doi: 10.1038/s41416-019-0581-8. [Epub ahead of print]

PMID:
31558804
5.

IKZF1/3 and CRL4-CRBN E3 ubiquitin ligase mutations and IMiD resistance in multiple myeloma.

Barrio S, Munawar U, Zhu YX, Giesen N, Shi CX, Da Viá M, Sanchez R, Bruins L, Demler T, Müller N, Haertle L, Garitano A, Steinbrunn T, Danhof S, Cuenca I, Barrio-Garcia C, Braggio E, Rosenwald A, Martinez-Lopez J, Rasche L, Raab MS, Stewart AK, Einsele H, Stühmer T, Kortüm KM.

Haematologica. 2019 Sep 26. pii: haematol.2019.217943. doi: 10.3324/haematol.2019.217943. [Epub ahead of print]

6.

Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population.

Ludwig H, Pönisch W, Knop S, Egle A, Hinke A, Schreder M, Lechner D, Hajek R, Gunsilius E, Petzer A, Weisel K, Niederwieser D, Einsele H, Willenbacher W, Rumpold H, Pour L, Jelinek T, Krenosz KJ, Meckl A, Nolte S, Melchardt T, Greil R, Zojer N.

Leuk Lymphoma. 2019 Sep 26:1-10. doi: 10.1080/10428194.2019.1666381. [Epub ahead of print]

PMID:
31556753
7.

Guidelines from the 2017 European Conference on Infections in Leukaemia for management of HHV-6 infection in patients with hematological malignancies and after hematopoietic stem cell transplantation.

Ward KN, Hill JA, Hubacek P, de la Camara R, Crocchiolo R, Einsele H, Navarro D, Robin C, Cordonnier C, Ljungman P.

Haematologica. 2019 Aug 29. pii: haematol.2019.223073. doi: 10.3324/haematol.2019.223073. [Epub ahead of print]

8.

Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis.

Knop S, Engelhardt M, Liebisch P, Meisner C, Holler E, Metzner B, Peest D, Kaufmann M, Bunjes D, Straka C, Fischer T, Sezer O, Hentrich M, Ostermann H, Bassermann F, Hess G, Hertenstein B, Freund M, Kropff M, Schmidt CA, Wolf HH, Jung W, Frickhofen N, Mielke S, Bargou RC, Maschmeyer G, Svaldi M, Langer CH, Gramatzki M, Hebart H, Kanz L, Einsele H; Deutsche Studiengruppe Multiples Myelom.

Leukemia. 2019 Aug 28. doi: 10.1038/s41375-019-0537-2. [Epub ahead of print]

PMID:
31462732
9.

CAR-T cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network.

Moreau P, Sonneveld P, Boccadoro M, Cook G, Mateos MV, Nahi H, Goldschmidt H, Dimopoulos MA, Lucio P, Bladé J, Delforge M, Hajek R, Ludwig H, Facon T, San Miguel JF, Einsele H.

Haematologica. 2019 Aug 22. pii: haematol.2019.224204. doi: 10.3324/haematol.2019.224204. [Epub ahead of print]

10.

The use of bispecific antibodies to optimize the outcome of patients with acute leukemia, lymphoma and multiple myeloma after SCT.

Einsele H, Rasche L, Topp MS, Martin Kortüm K, Duell J.

Bone Marrow Transplant. 2019 Aug;54(Suppl 2):721-726. doi: 10.1038/s41409-019-0596-z.

PMID:
31431702
11.

ROR1-CAR T cells are effective against lung and breast cancer in advanced microphysiologic 3D tumor models.

Wallstabe L, Göttlich C, Nelke LC, Kühnemundt J, Schwarz T, Nerreter T, Einsele H, Walles H, Dandekar G, Nietzer SL, Hudecek M.

JCI Insight. 2019 Sep 19;4(18). pii: 126345. doi: 10.1172/jci.insight.126345.

12.

EZH2 mutations and impact on clinical outcome - an analysis in 1604 patients with newly diagnosed acute myeloid leukemia.

Stasik S, Middeke JM, Kramer M, Röllig C, Krämer A, Scholl S, Hochhaus A, Crysandt M, Brümmendorf TH, Naumann R, Steffen B, Kunzmann V, Einsele H, Schaich M, Burchert A, Neubauer A, Schäfer-Eckart K, Schliemann C, Krause S, Herbst R, Hänel M, Frickhofen N, Noppeney R, Kaiser U, Baldus CD, Kaufmann M, Rácil Z, Platzbecker U, Berdel WE, Mayer J, Serve H, Müller-Tidow C, Ehninger G, Bornhäuser M, Schetelig J, Thiede C.

Haematologica. 2019 Aug 14. pii: haematol.2019.222323. doi: 10.3324/haematol.2019.222323. [Epub ahead of print]

13.

Hierarchy of mono- and biallelic TP53 alterations in multiple myeloma cell fitness.

Munawar U, Rasche L, Müller N, Vogt C, Da-Via M, Haertle L, Arampatzi P, Dietrich S, Roth M, Garitano-Trojaola A, Steinhardt MJ, Strifler S, Gallardo M, Martinez-Lopez J, Bargou RC, Heckel T, Einsele H, Stühmer T, Kortüm KM, Barrio S.

Blood. 2019 Sep 5;134(10):836-840. doi: 10.1182/blood.2019000080. Epub 2019 Jul 24. No abstract available.

PMID:
31340981
14.

Exploration of Artificial Intelligence Use with ARIES in Multiple Myeloma Research.

Loda S, Krebs J, Danhof S, Schreder M, Solimando AG, Strifler S, Rasche L, Kortüm M, Kerscher A, Knop S, Puppe F, Einsele H, Bittrich M.

J Clin Med. 2019 Jul 9;8(7). pii: E999. doi: 10.3390/jcm8070999.

15.

High-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor Microenvironment.

Solimando AG, Da Vià MC, Cicco S, Leone P, Di Lernia G, Giannico D, Desantis V, Frassanito MA, Morizio A, Delgado Tascon J, Melaccio A, Saltarella I, Ranieri G, Ria R, Rasche L, Kortüm KM, Beilhack A, Racanelli V, Vacca A, Einsele H.

J Clin Med. 2019 Jul 9;8(7). pii: E997. doi: 10.3390/jcm8070997. Review.

16.

Response to daratumumab in rituximab-resistant EBV-associated PTLD following allogenic stem cell transplantation from an EBV seronegative donor.

Strunz PP, Schmalzing M, Heidemeier A, Rasche L, Einsele H, Kortüm KM.

Leuk Lymphoma. 2019 Jul 18:1-4. doi: 10.1080/10428194.2019.1636981. [Epub ahead of print] No abstract available.

PMID:
31317812
17.

Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-T.

Nerreter T, Letschert S, Götz R, Doose S, Danhof S, Einsele H, Sauer M, Hudecek M.

Nat Commun. 2019 Jul 17;10(1):3137. doi: 10.1038/s41467-019-10948-w.

18.

Comparison of 11C-Choline and 11C-Methionine PET/CT in Multiple Myeloma.

Lapa C, Kircher M, Da Via M, Schreder M, Rasche L, Kortüm KM, Einsele H, Buck AK, Hänscheid H, Samnick S.

Clin Nucl Med. 2019 Aug;44(8):620-624. doi: 10.1097/RLU.0000000000002638.

PMID:
31274607
19.

Hereditary spherocytosis is associated with decreased pyruvate kinase activity due to impaired structural integrity of the red blood cell membrane.

Andres O, Loewecke F, Morbach H, Kraus S, Einsele H, Eber S, Speer CP.

Br J Haematol. 2019 Jul 5. doi: 10.1111/bjh.16084. [Epub ahead of print]

PMID:
31273765
20.

The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells.

Mestermann K, Giavridis T, Weber J, Rydzek J, Frenz S, Nerreter T, Mades A, Sadelain M, Einsele H, Hudecek M.

Sci Transl Med. 2019 Jul 3;11(499). pii: eaau5907. doi: 10.1126/scitranslmed.aau5907.

PMID:
31270272
21.

Bortezomib consolidation following autologous transplant in younger and older patients with newly diagnosed multiple myeloma in two phase III trials.

Straka C, Knop S, Vogel M, Müller J, Kropff M, Metzner B, Langer C, Sayer H, Jung W, Dürk HA, Salwender H, Wandt H, Bassermann F, Gramatzki M, Rösler W, Wolf HH, Brugger W, Fischer T, Liebisch P, Engelhardt M, Einsele H.

Eur J Haematol. 2019 Sep;103(3):255-267. doi: 10.1111/ejh.13281. Epub 2019 Jul 19.

PMID:
31231828
22.

Clinical Approach to the Patient in Critical State Following Immunotherapy and/or Stem Cell Transplantation: Guideline for the On-Call Physician.

Constantinescu C, Bodolea C, Pasca S, Teodorescu P, Dima D, Rus I, Tat T, Achimas-Cadariu P, Tanase A, Tomuleasa C, Einsele H.

J Clin Med. 2019 Jun 20;8(6). pii: E884. doi: 10.3390/jcm8060884. Review.

23.

Comparison of 11C-Choline and 11C-Methionine PET/CT in Multiple Myeloma.

Lapa C, Kircher M, Da Via M, Schreder M, Rasche L, Kortüm KM, Einsele H, Buck AK, Hänscheid H, Samnick S.

Clin Nucl Med. 2019 Jun 13. doi: 10.1097/RLU.0000000000002638. [Epub ahead of print]

PMID:
31205144
24.

International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders.

Hillengass J, Usmani S, Rajkumar SV, Durie BGM, Mateos MV, Lonial S, Joao C, Anderson KC, García-Sanz R, Riva E, Du J, van de Donk N, Berdeja JG, Terpos E, Zamagni E, Kyle RA, San Miguel J, Goldschmidt H, Giralt S, Kumar S, Raje N, Ludwig H, Ocio E, Schots R, Einsele H, Schjesvold F, Chen WM, Abildgaard N, Lipe BC, Dytfeld D, Wirk BM, Drake M, Cavo M, Lahuerta JJ, Lentzsch S.

Lancet Oncol. 2019 Jun;20(6):e302-e312. doi: 10.1016/S1470-2045(19)30309-2. Review. Erratum in: Lancet Oncol. 2019 Jul;20(7):e346.

PMID:
31162104
25.

Invasive Fungal Infection.

von Lilienfeld-Toal M, Wagener J, Einsele H, Cornely OA, Kurzai O.

Dtsch Arztebl Int. 2019 Apr 19;116(16):271-278. doi: 10.3238/arztebl.2019.0271.

26.

Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7).

Ljungman P, de la Camara R, Robin C, Crocchiolo R, Einsele H, Hill JA, Hubacek P, Navarro D, Cordonnier C, Ward KN; 2017 European Conference on Infections in Leukaemia group.

Lancet Infect Dis. 2019 Aug;19(8):e260-e272. doi: 10.1016/S1473-3099(19)30107-0. Epub 2019 May 29. Review.

PMID:
31153807
27.

Development and evaluation of a whole blood-based approach for flow cytometric quantification of CD154+ mould-reactive T cells.

Weis P, Helm J, Page L, Lauruschkat CD, Lazariotou M, Einsele H, Loeffler J, Ullmann AJ, Wurster S.

Med Mycol. 2019 May 16. pii: myz038. doi: 10.1093/mmy/myz038. [Epub ahead of print]

PMID:
31095327
28.

Functionally Defective T Cells After Chemotherapy of B-Cell Malignancies Can Be Activated by the Tetravalent Bispecific CD19/CD3 Antibody AFM11.

Duell J, Lukic DS, Karg M, Reusch U, Koch J, Zhukovsky EA, Rajkovic E, Treder M, Rasche L, Eisele F, Einsele H, Topp MS.

J Immunother. 2019 Jun;42(5):180-188. doi: 10.1097/CJI.0000000000000267.

PMID:
31090657
29.

Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).

Saraceni F, Labopin M, Brecht A, Kröger N, Eder M, Tischer J, Labussière-Wallet H, Einsele H, Beelen D, Bunjes D, Niederwieser D, Bochtler T, Savani BN, Mohty M, Nagler A.

J Hematol Oncol. 2019 Apr 25;12(1):44. doi: 10.1186/s13045-019-0727-4.

30.

[Treatment of multiple myeloma with elotuzumab plus pomalidomide and dexamethasone].

Rasche L, Einsele H, Nitschmann S.

Internist (Berl). 2019 Jun;60(6):658-660. doi: 10.1007/s00108-019-0592-9. German. No abstract available.

PMID:
30941437
31.

Side Effects of CXC-Chemokine Receptor 4-Directed Endoradiotherapy with Pentixather Before Hematopoietic Stem Cell Transplantation.

Maurer S, Herhaus P, Lippenmeyer R, Hänscheid H, Kircher M, Schirbel A, Maurer HC, Buck AK, Wester HJ, Einsele H, Grigoleit GU, Keller U, Lapa C.

J Nucl Med. 2019 Oct;60(10):1399-1405. doi: 10.2967/jnumed.118.223420. Epub 2019 Mar 8.

PMID:
30850502
32.

Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis.

Robin M, de Wreede LC, Wolschke C, Schetelig J, Eikema DJ, Van Lint MT, Knelange NS, Beelen D, Brecht A, Niederwieser D, Vitek A, Bethge W, Arnold R, Finke J, Volin L, Yakoub-Agha I, Nagler A, Poiré X, Einsele H, Chevallier P, Holler E, Ljungman P, Robinson S, Radujkovic A, McLornan D, Chalandon Y, Kröger N.

Haematologica. 2019 Sep;104(9):1782-1788. doi: 10.3324/haematol.2018.205211. Epub 2019 Feb 7.

33.

Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension.

Bringhen S, Milan A, D'Agostino M, Ferri C, Wäsch R, Gay F, Larocca A, Offidani M, Zweegman S, Terpos E, Goldschmidt H, Cavo M, Ludwig H, Driessen C, Auner HW, Caers J, Gramatzki M, Dimopoulos MA, Boccadoro M, Einsele H, Sonneveld P, Engelhardt M.

J Intern Med. 2019 Jul;286(1):63-74. doi: 10.1111/joim.12882. Epub 2019 Apr 8.

PMID:
30725503
34.

Comparative Analysis of Inflammatory Cytokine Release and Alveolar Epithelial Barrier Invasion in a Transwell® Bilayer Model of Mucormycosis.

Belic S, Page L, Lazariotou M, Waaga-Gasser AM, Dragan M, Springer J, Loeffler J, Morton CO, Einsele H, Ullmann AJ, Wurster S.

Front Microbiol. 2019 Jan 8;9:3204. doi: 10.3389/fmicb.2018.03204. eCollection 2018.

35.

Author Correction: Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma.

Went M, Sud A, Försti A, Halvarsson BM, Weinhold N, Kimber S, van Duin M, Thorleifsson G, Holroyd A, Johnson DC, Li N, Orlando G, Law PJ, Ali M, Chen B, Mitchell JS, Gudbjartsson DF, Kuiper R, Stephens OW, Bertsch U, Broderick P, Campo C, Bandapalli OR, Einsele H, Gregory WA, Gullberg U, Hillengass J, Hoffmann P, Jackson GH, Jöckel KH, Johnsson E, Kristinsson SY, Mellqvist UH, Nahi H, Easton D, Pharoah P, Dunning A, Peto J, Canzian F, Swerdlow A, Eeles RA, Kote-Jarai Z, Muir K, Pashayan N; PRACTICAL consortium, Nickel J, Nöthen MM, Rafnar T, Ross FM, da Silva Filho MI, Thomsen H, Turesson I, Vangsted A, Andersen NF, Waage A, Walker BA, Wihlborg AK, Broyl A, Davies FE, Thorsteinsdottir U, Langer C, Hansson M, Goldschmidt H, Kaiser M, Sonneveld P, Stefansson K, Morgan GJ, Hemminki K, Nilsson B, Houlston RS.

Nat Commun. 2019 Jan 10;10(1):213. doi: 10.1038/s41467-018-08107-8.

36.

Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology.

Went M, Sud A, Speedy H, Sunter NJ, Försti A, Law PJ, Johnson DC, Mirabella F, Holroyd A, Li N, Orlando G, Weinhold N, van Duin M, Chen B, Mitchell JS, Mansouri L, Juliusson G, Smedby KE, Jayne S, Majid A, Dearden C, Allsup DJ, Bailey JR, Pratt G, Pepper C, Fegan C, Rosenquist R, Kuiper R, Stephens OW, Bertsch U, Broderick P, Einsele H, Gregory WM, Hillengass J, Hoffmann P, Jackson GH, Jöckel KH, Nickel J, Nöthen MM, da Silva Filho MI, Thomsen H, Walker BA, Broyl A, Davies FE, Hansson M, Goldschmidt H, Dyer MJS, Kaiser M, Sonneveld P, Morgan GJ, Hemminki K, Nilsson B, Catovsky D, Allan JM, Houlston RS.

Blood Cancer J. 2018 Dec 21;9(1):1. doi: 10.1038/s41408-018-0162-8.

37.

Chimeric Antigen Receptor Library Screening Using a Novel NF-κB/NFAT Reporter Cell Platform.

Rydzek J, Nerreter T, Peng H, Jutz S, Leitner J, Steinberger P, Einsele H, Rader C, Hudecek M.

Mol Ther. 2019 Feb 6;27(2):287-299. doi: 10.1016/j.ymthe.2018.11.015. Epub 2018 Nov 20.

PMID:
30573301
38.

Human NK cells adapt their immune response towards increasing multiplicities of infection of Aspergillus fumigatus.

Marischen L, Englert A, Schmitt AL, Einsele H, Loeffler J.

BMC Immunol. 2018 Dec 18;19(1):39. doi: 10.1186/s12865-018-0276-6.

39.

Immunomodulation as a Therapy for Aspergillus Infection: Current Status and Future Perspectives.

Lauruschkat CD, Einsele H, Loeffler J.

J Fungi (Basel). 2018 Dec 14;4(4). pii: E137. doi: 10.3390/jof4040137. Review.

40.

[Diagnostic and therapeutic considerations on recurrence of multiple myeloma : A current overview].

Kortüm KM, Einsele H.

Internist (Berl). 2019 Jan;60(1):34-41. doi: 10.1007/s00108-018-0528-9. Review. German.

PMID:
30536028
41.

Clinical and biological characteristics of myeloma patients influence response to elotuzumab combination therapy.

Danhof S, Strifler S, Hose D, Kortüm M, Bittrich M, Hefner J, Einsele H, Knop S, Schreder M.

J Cancer Res Clin Oncol. 2019 Mar;145(3):561-571. doi: 10.1007/s00432-018-2807-1. Epub 2018 Dec 5.

PMID:
30519736
42.

CAR T cells targeting αvβ3 integrin are effective against advanced cancer in preclinical models.

Wallstabe L, Mades A, Frenz S, Einsele H, Rader C, Hudecek M.

Adv Cell Gene Ther. 2018 Sep;1(2). pii: e11. doi: 10.1002/acg2.11. Epub 2018 Jul 10.

43.

Hexokinase-2 Expression in 11C-Methionine-Positive, 18F-FDG-Negative Multiple Myeloma.

Kircher S, Stolzenburg A, Kortüm KM, Kircher M, Da Via M, Samnick S, Buck AK, Einsele H, Rosenwald A, Lapa C.

J Nucl Med. 2019 Mar;60(3):348-352. doi: 10.2967/jnumed.118.217539. Epub 2018 Nov 2.

PMID:
30389821
44.

Haploidentical versus unrelated allogeneic stem cell transplantation for relapsed/refractory acute myeloid leukemia: a report on 1578 patients from the Acute Leukemia Working Party of the EBMT.

Brissot E, Labopin M, Ehninger G, Stelljes M, Brecht A, Ganser A, Tischer J, Kröger N, Afanasyev B, Finke J, Elmaagacli A, Einsele H, Mohty M, Nagler A.

Haematologica. 2019 Mar;104(3):524-532. doi: 10.3324/haematol.2017.187450. Epub 2018 Oct 25.

45.

Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma.

Leleu X, Martin TG, Einsele H, Lyons RM, Durie BGM, Iskander KS, Ailawadhi S.

Clin Lymphoma Myeloma Leuk. 2019 Jan;19(1):9-22. doi: 10.1016/j.clml.2018.08.016. Epub 2018 Sep 5. Review.

PMID:
30287200
46.

Proteome Analysis Reveals the Conidial Surface Protein CcpA Essential for Virulence of the Pathogenic Fungus Aspergillus fumigatus.

Voltersen V, Blango MG, Herrmann S, Schmidt F, Heinekamp T, Strassburger M, Krüger T, Bacher P, Lother J, Weiss E, Hünniger K, Liu H, Hortschansky P, Scheffold A, Löffler J, Krappmann S, Nietzsche S, Kurzai O, Einsele H, Kniemeyer O, Filler SG, Reichard U, Brakhage AA.

MBio. 2018 Oct 2;9(5). pii: e01557-18. doi: 10.1128/mBio.01557-18.

47.

Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life.

Greil C, Engelhardt M, Ihorst G, Schoeller K, Bertz H, Marks R, Zeiser R, Duyster J, Einsele H, Finke J, Wäsch R.

Haematologica. 2019 Feb;104(2):370-379. doi: 10.3324/haematol.2018.200881. Epub 2018 Sep 20.

48.

Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma.

Went M, Sud A, Försti A, Halvarsson BM, Weinhold N, Kimber S, van Duin M, Thorleifsson G, Holroyd A, Johnson DC, Li N, Orlando G, Law PJ, Ali M, Chen B, Mitchell JS, Gudbjartsson DF, Kuiper R, Stephens OW, Bertsch U, Broderick P, Campo C, Bandapalli OR, Einsele H, Gregory WA, Gullberg U, Hillengass J, Hoffmann P, Jackson GH, Jöckel KH, Johnsson E, Kristinsson SY, Mellqvist UH, Nahi H, Easton D, Pharoah P, Dunning A, Peto J, Canzian F, Swerdlow A, Eeles RA, Kote-Jarai Z, Muir K, Pashayan N, Nickel J, Nöthen MM, Rafnar T, Ross FM, da Silva Filho MI, Thomsen H, Turesson I, Vangsted A, Andersen NF, Waage A, Walker BA, Wihlborg AK, Broyl A, Davies FE, Thorsteinsdottir U, Langer C, Hansson M, Goldschmidt H, Kaiser M, Sonneveld P, Stefansson K, Morgan GJ, Hemminki K, Nilsson B, Houlston RS; PRACTICAL consortium.

Nat Commun. 2018 Sep 13;9(1):3707. doi: 10.1038/s41467-018-04989-w. Erratum in: Nat Commun. 2019 Jan 10;10(1):213.

49.

Evaluation of Aspergillus and Mucorales specific T-cells and peripheral blood mononuclear cell cytokine signatures as biomarkers of environmental mold exposure.

Page L, Weis P, Müller T, Dittrich M, Lazariotou M, Dragan M, Waaga-Gasser AM, Helm J, Dandekar T, Einsele H, Löffler J, Ullmann AJ, Wurster S.

Int J Med Microbiol. 2018 Dec;308(8):1018-1026. doi: 10.1016/j.ijmm.2018.09.002. Epub 2018 Sep 3.

PMID:
30201279
50.

Validation of a simplified in vitro Transwell® model of the alveolar surface to assess host immunity induced by different morphotypes of Aspergillus fumigatus.

Morton CO, Wurster S, Fliesser M, Ebel F, Page L, Hünniger K, Kurzai O, Schmitt AL, Michel D, Springer J, Einsele H, Loeffler J.

Int J Med Microbiol. 2018 Dec;308(8):1009-1017. doi: 10.1016/j.ijmm.2018.09.001. Epub 2018 Sep 3.

PMID:
30197238

Supplemental Content

Loading ...
Support Center